|
|
Volumn 343, Issue 7828, 2011, Pages
|
|
Off-label prescribing in macular degeneration
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
BEVACIZUMAB;
RANIBIZUMAB;
ANGIOGENESIS INHIBITOR;
MONOCLONAL ANTIBODY;
PRESCRIPTION DRUG;
COST CONTROL;
DRUG COST;
DRUG INDUSTRY;
DRUG LEGISLATION;
DRUG MARKETING;
DRUG SAFETY;
EVIDENCE BASED MEDICINE;
FINANCIAL MANAGEMENT;
HUMAN RELATION;
INFORMED CONSENT;
LICENCE;
MASS MEDIUM;
MEDICAL DECISION MAKING;
NATIONAL HEALTH SERVICE;
OFF LABEL PRESCRIPTION;
PHYSICIAN;
PRESCRIPTION;
PRIMARY MEDICAL CARE;
PRIORITY JOURNAL;
PUBLISHING;
RETINA MACULA DEGENERATION;
SHORT SURVEY;
ARTICLE;
CLINICAL PRACTICE;
ECONOMICS;
HUMAN;
OFF LABEL DRUG USE;
UNITED KINGDOM;
ANGIOGENESIS INHIBITORS;
ANTIBODIES, MONOCLONAL, HUMANIZED;
GREAT BRITAIN;
HUMANS;
LEGISLATION, DRUG;
MACULAR DEGENERATION;
OFF-LABEL USE;
PHYSICIAN'S PRACTICE PATTERNS;
PRESCRIPTION DRUGS;
|
|
EID: 80054833259
PISSN: 09598146
EISSN: 17561833
Source Type: Journal
DOI: 10.1136/bmj.d6778 Document Type: Short Survey |
|
Times cited : (4)
|
|
References (0)
|
